Novo Nordisk Shares Climb as Oral Wegovy Hits 18,410 First-Week Prescriptions and Goldman Issues Buy Rating

On January 23, 2026, Novo Nordisk shares advanced after the new oral Wegovy weight-loss pill logged 18,410 first-week prescriptions and outpaced Eli Lilly's Zepbound. The rally was reinforced by a Buy rating from Goldman Sachs, as investors focused on the drugmaker's earnings outlook and expanding position in the GLP-1 obesity market.